Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrolife ABCHIX:VITRS 74 EV-to-EBIT is -2.75 as of Aug. 22, 2026. GuruFocus rates CHIX:VITRS with a GF Score™ of 74/100 and a GF Value™ of kr141.13 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Vitrolife AB ranks worse than 211416.28% on this metric.
The historical rank and industry rank for Vitrolife AB's EV-to-EBIT or its related term are showing as below:
CHIX:VITRs'
s EV-to-EBIT Range Over the Past 10 Years
Min: -10.08 Med: 40.67 Max: 152.15
Current: -2.75
During the past 13 years, the highest EV-to-EBIT of Vitrolife AB was 152.15. The lowest was -10.08. And the median was 40.67.
CHIX:VITRs's EV-to-EBIT is ranked worse than 100% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 18.87
vs CHIX:VITRs: -2.75
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vitrolife AB's Enterprise Value for the quarter that ended in Jun. 2026 was kr15,104 Mil.
Vitrolife AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-4,776 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB EV-to-EBIT Related Terms
Vitrolife AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VITRS vs ABT, SYK, MDT: EV-to-EBIT Comparison
For the Medical Devices subindustry, Vitrolife AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's EV-to-EBIT falls into.
Vitrolife AB's current Enterprise Value is kr13,112 Mil.
Vitrolife AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-4,776 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (CHIX:VITRS) has a EV-to-EBIT of -2.75 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vitrolife AB and its competitors. According to the industry distribution chart, Vitrolife AB ranks #999999 out of 473 companies in the Medical Devices & Instruments industry.
Is Vitrolife AB's EV-to-EBIT too high?
Vitrolife AB's current EV-to-EBIT is -2.75. Based on the distribution chart, Vitrolife AB ranks #999999 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vitrolife AB has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #999999 out of 473 companies for EV-to-EBIT. This places Vitrolife AB in the lower half of its industry. The industry median EV-to-EBIT is 18.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.87, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current EV-to-EBIT is -2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr141.13, compared to a current price of kr86.38 — trading 38.8% below its estimated fair value. The current EV-to-EBIT is -2.75. Vitrolife AB's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current EV-to-EBIT is -2.75 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr86.38 is trading 38.8% below its estimated GF Value™ of kr141.13.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for CHIX:VITRS:
EV-to-EBIT: -2.75
GF Value™: kr141.13 vs. price of kr86.38 (38.8% below fair value)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
74GF Score
Get the complete analysis for CHIX:VITRS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
